Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A short term (12 h) treatment of the reporters pSMR5:GUS and pSMR7:GUS with a relatively high concentration of MTX (40 nM), a treatment condition chosen based on preliminary effectiveness studies with CYCB1.1 (Fig
The foremost limitation is the absence of large-scale, randomized, and well-controlled clinical trials capable of establishing definitive evidence of safety and efficacy in human populations
Factors like dosage, frequency of intake, individual metabolism, and lifestyle habits can all affect the timeframe
Individuals with intestinal disorders like Crohns or Celiac Disease
US$ 29.40
US$ 26.77
US$ 20.65
US$ 22.96
US$ 28.49
US$ 28.63
US$ 26.34
US$ 21.52
US$ 23.83
